Free Trial

Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Novo Nordisk A/S logo
$58.77 -0.40 (-0.67%)
Closing price 10/2/2025 03:59 PM Eastern
Extended Trading
$58.35 -0.42 (-0.72%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Novo Nordisk A/S Stock (NYSE:NVO)

Advanced

Key Stats

Today's Range
$58.00
$59.12
50-Day Range
$45.31
$71.67
52-Week Range
$45.05
$120.56
Volume
11.92 million shs
Average Volume
15.72 million shs
Market Capitalization
$262.42 billion
P/E Ratio
16.15
Dividend Yield
1.40%
Price Target
$77.50
Consensus Rating
Moderate Buy

Company Overview

Novo Nordisk A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

NVO MarketRank™: 

Novo Nordisk A/S scored higher than 90% of companies evaluated by MarketBeat, and ranked 112th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novo Nordisk A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 7 buy ratings, 9 hold ratings, and 1 sell rating.

  • Upside Potential

    Novo Nordisk A/S has a consensus price target of $77.50, representing about 31.9% upside from its current price of $58.77.

  • Amount of Analyst Coverage

    Novo Nordisk A/S has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Novo Nordisk A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Novo Nordisk A/S are expected to grow by 21.35% in the coming year, from $3.84 to $4.66 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novo Nordisk A/S is 16.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.79.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novo Nordisk A/S is 16.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.39.

  • Price to Earnings Growth Ratio

    Novo Nordisk A/S has a PEG Ratio of 2.27. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novo Nordisk A/S has a P/B Ratio of 12.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Novo Nordisk A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.64% of the outstanding shares of Novo Nordisk A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Novo Nordisk A/S has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novo Nordisk A/S has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Novo Nordisk A/S pays a meaningful dividend of 1.39%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novo Nordisk A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novo Nordisk A/S is 22.53%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 17.60% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

  • Read more about Novo Nordisk A/S's dividend.
  • Percentage of Shares Shorted

    0.64% of the outstanding shares of Novo Nordisk A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Novo Nordisk A/S has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novo Nordisk A/S has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Novo Nordisk A/S has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 79 news articles for Novo Nordisk A/S this week, compared to 66 articles on an average week.
  • Search Interest

    254 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 37% compared to the previous 30 days.
  • MarketBeat Follows

    87 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 28% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.

  • Percentage Held by Institutions

    Only 11.54% of the stock of Novo Nordisk A/S is held by institutions.

  • Read more about Novo Nordisk A/S's insider trading history.
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVO Stock News Headlines

HSBC Upgrades Novo Nordisk A (NVO)
Novo Nordisk A/S (NYSE:NVO) Upgraded at HSBC
A Huge Shift Is Underway in America
Wall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous. He says it's about to change everything you know about money.tc pixel
BMO Capital Remains a Hold on Novo Nordisk (NVO)
Novo Nordisk A/S (NYSE:NVO) Trading 6.6% Higher After Analyst Upgrade
See More Headlines

NVO Stock Analysis - Frequently Asked Questions

Novo Nordisk A/S's stock was trading at $86.02 at the start of the year. Since then, NVO stock has decreased by 31.7% and is now trading at $58.7720.

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings data on Wednesday, August, 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm earned $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 78.64% and a net margin of 35.60%.
Read the conference call transcript
.

Shares of Novo Nordisk A/S split on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly created shares were payable to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Novo Nordisk A/S subsidiaries include these companies: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and more.

Top institutional shareholders of Novo Nordisk A/S include Bank of New Hampshire, Cacti Asset Management LLC, Armstrong Henry H Associates Inc. and GAMMA Investing LLC.
View institutional ownership trends
.

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY).

Company Calendar

Last Earnings
8/06/2025
Record date for 8/26 Dividend
8/18/2025
Ex-Dividend for 8/26 Dividend
8/18/2025
Dividend Payable
8/26/2025
Today
10/03/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NVO
CIK
353278
Employees
77,349
Year Founded
1923

Price Target and Rating

High Price Target
$160.00
Low Price Target
$47.00
Potential Upside/Downside
+31.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
19 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.64
Trailing P/E Ratio
16.15
Forward P/E Ratio
15.31
P/E Growth
2.27
Net Income
$14.64 billion
Net Margins
35.60%
Pretax Margin
45.11%
Return on Equity
78.64%
Return on Assets
24.51%

Debt

Debt-to-Equity Ratio
0.52
Current Ratio
0.78
Quick Ratio
0.56

Sales & Book Value

Annual Sales
$42.12 billion
Price / Sales
6.23
Cash Flow
$3.87 per share
Price / Cash Flow
15.17
Book Value
$4.66 per share
Price / Book
12.61

Miscellaneous

Outstanding Shares
4,465,000,000
Free Float
4,461,875,000
Market Cap
$262.42 billion
Optionable
Optionable
Beta
0.68

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:NVO) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners